Cargando…

Effect of Dipeptidyl Peptidase-4 Inhibitors on Bone Metabolism and the Possible Underlying Mechanisms

Diabetes mellitus has been demonstrated to be closely associated with osteoporosis. Accordingly, hypoglycemic therapy is considered effective in treating metabolic bone disease. Recently, the effects of dipeptidyl peptidase-4 (DPP-4) inhibitors, a new type of antidiabetic drug, on bone metabolism ha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Yinqiu, Zhao, Chenhe, Liang, Jing, Yu, Mingxiang, Qu, Xinhua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2017
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5524773/ https://www.ncbi.nlm.nih.gov/pubmed/28790917 http://dx.doi.org/10.3389/fphar.2017.00487

Ejemplares similares

Effect of Sodium-Glucose Co-transporter 2 Inhibitors on Bone Metabolism and Fracture Risk
por: Ye, Yangli, et al.
Publicado: (2019)

The Impact of Glucagon-Like Peptide-1 on Bone Metabolism and Its Possible Mechanisms
por: Zhao, Chenhe, et al.
Publicado: (2017)

New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
por: Cui, Chenkai, et al.
Publicado: (2022)

Risk of Cardiovascular Events and Medical Cost of Dapagliflozin and Dipeptidyl Peptidase-4 Inhibitors
por: Seong, Jong-Mi, et al.
Publicado: (2021)

Renoprotective Effect of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus
por: Esaki, Hiroki, et al.
Publicado: (2017)

Prospect of Sodium–Glucose Co-transporter 2 Inhibitors Combined With Insulin for the Treatment of Type 2 Diabetes
por: Yang, Yinqiu, et al.
Publicado: (2020)

Collagenous Colitis Possibly Associated with Dipeptidyl Peptidase-4 Inhibitor
por: Takedomi, Hironobu, et al.
Publicado: (2022)

The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence
por: Zhang, Tianli, et al.
Publicado: (2021)

Dipeptidyl peptidase-4 inhibitors: Novel mechanism of actions
por: Singh, Awadhesh Kumar
Publicado: (2014)

The Multiple Biological Functions of Dipeptidyl Peptidase-4 in Bone Metabolism
por: Yang, Qiu, et al.
Publicado: (2022)

Soluble Dipeptidyl Peptidase-4 Induces Fibroblast Activation Through Proteinase-Activated Receptor-2
por: Lee, Shih-Yi, et al.
Publicado: (2020)

Serum and Adipose Dipeptidyl Peptidase 4 in Cardiovascular Surgery Patients: Influence of Dipeptidyl Peptidase 4 Inhibitors
por: Shibasaki, Ikuko, et al.
Publicado: (2022)

Roles and Mechanisms of Dipeptidyl Peptidase 4 Inhibitors in Vascular Aging
por: Cao, Fen, et al.
Publicado: (2021)

Dipeptidyl peptidase 4 expression is not associated with an activated fibroblast phenotype in idiopathic pulmonary fibrosis
por: Kadefors, Måns, et al.
Publicado: (2022)

Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors vs. Dipeptidyl Peptidase-4 Inhibitors in Frail People With Diabetes Who Were Recently Hospitalized
por: Wood, Stephen J, et al.
Publicado: (2022)

The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors
por: Kim, Na-Hyung, et al.
Publicado: (2014)

Further Possible Mechanisms of Dipeptidyl Peptidase-4 Inhibitors to Decrease Blood Glucose in Subjects with Type 2 Diabetes
por: Koshiyama, Hiroyuki
Publicado: (2011)

Dipeptidyl Peptidase-4 Inhibitors Use and Relative Risk of Ischemic Cerebrovascular Disease in Type 2 Diabetic Patients in a Case-Control Study
por: Lai, Shih-Wei, et al.
Publicado: (2017)

Health economic evaluation of dipeptidyl peptidase-4 inhibitors
por: Garg, Vishvas
Publicado: (2011)

Navigating the chemical space of dipeptidyl peptidase-4 inhibitors
por: Shoombuatong, Watshara, et al.
Publicado: (2015)

Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Outcome
por: Kim, Kwang-il
Publicado: (2018)

Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid
por: Tasanen, Kaisa, et al.
Publicado: (2019)

Dipeptidyl peptidase 4 inhibitors: Applications in innate immunity?
por: Yazbeck, R., et al.
Publicado: (2021)

Role of Dipeptidyl Peptidase 4 Inhibitors in Antidiabetic Treatment
por: Yin, Ruili, et al.
Publicado: (2022)

The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
por: Kanasaki, Keizo
Publicado: (2018)

Association Between Bone Mineral Density, Bone Turnover Markers, and Serum Cholesterol Levels in Type 2 Diabetes
por: Yang, Yinqiu, et al.
Publicado: (2018)

Angioedema associated with dipeptidyl peptidase-IV inhibitors
por: Cassano, Nicoletta, et al.
Publicado: (2021)

The influence of dipeptidyl peptidase-4 inhibitor on the progression of type B intramural hematoma
por: Chen, Qu, et al.
Publicado: (2022)

Dipeptidyl Peptidase-4 at the Interface Between Inflammation and Metabolism
por: Trzaskalski, Natasha A, et al.
Publicado: (2020)

Head-to-Head Comparison of the Hypoglycemic Efficacy and Safety Between Dipeptidyl Peptidase-4 Inhibitors and α-Glucosidase Inhibitors in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials
por: Li, Zhaoliang, et al.
Publicado: (2019)

Association between serum levels of bone turnover markers and bone mineral density in men and women with type 2 diabetes mellitus
por: Zhao, Chenhe, et al.
Publicado: (2019)

Dipeptidyl peptidase‐4 inhibitors and prevention of bone fractures: Effects beyond glyemic control
por: Yabe, Daisuke, et al.
Publicado: (2012)

Effect of Dipeptidyl Peptidase-4 Inhibitors on the Risk of Bone Fractures in a Korean Population
por: Ustulin, Morena, et al.
Publicado: (2019)

Correction: The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
por: Kanasaki, Keizo
Publicado: (2019)

Increasing Age Associated with Higher Dipeptidyl Peptidase-4 Inhibition Rate Is a Predictive Factor for Efficacy of Dipeptidyl Peptidase-4 Inhibitors
por: Hong, Sangmo, et al.
Publicado: (2022)

First-in-Human, Double-Blind, Randomized, Placebo-Controlled Trial of TQ-F3083, a New Dipeptidyl Peptidase-4 Inhibitor, in Healthy Chinese Adults
por: Liu, Jingrui, et al.
Publicado: (2021)

Impact of glucagon-like peptide 1 receptor agonist liraglutide and dipeptidyl peptidase-4 inhibitor sitagliptin on bowel cleaning and gastrointestinal symptoms in type 2 diabetes
por: Tong, Yan, et al.
Publicado: (2023)

The Role of Dipeptidyl Peptidase – 4 Inhibitors in Diabetic Kidney Disease
por: Panchapakesan, Usha, et al.
Publicado: (2015)

Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions
por: Shao, Shiying, et al.
Publicado: (2020)

Bullous pemphigoid associated with use of dipeptidyl peptidase-4 inhibitor
por: Kano, Yasuhiro, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_edj88pdvnl99g6fjbcitfngk0e